Efficacy of zincoderm G cream against wound infection by Pseudomonas aeruginosa in Sprague-Dawley rats

S. M. Satyam, K. Laxminarayana Bairy, S. Musharaf, D. Fernandes, V. Shashidhar

Abstract


Background: Zincoderm G cream is a fixed dose combination of clobetasol, gentamicin and zinc. Studies have been carried out for efficacy of each component such as clobetasol and gentamicin in bacterial infections, but as fixed dose combination including zinc has not been reported yet. Hence, a study was planned to assess the efficacy of Zincoderm G cream in experimental wound infection by Pseudomonas aerugionosa.

Methods: In the experiment a total of 18 Sprague-Dawley rats (male, pathogen free, 6-8 weeks old) were used. The rats were divided into three groups of six rats each. 25-30 mg of test drugs (Zincoderm G cream with or without zinc) was applied on Pseudomonas aeruginosa infected burn wound affected area of back of rats for 2 weeks. Bacterial infection was assessed by quantification of bacteria.

Results: There was 80% mortality observed in P. aeruginosa infected toxic control (cream base) group. Whereas, only 40% mortality was seen in both Zincoderm G cream with/without zinc groups, which were inoculated with P. aeruginosa. Bacterial concentration (Number of colony forming unit/ml wound fluid) was significantly decreased (p<0.001) in P. aeruginosa infected rats treated with Zincoderm G cream with zinc when compared with P. aeruginosa infected control (untreated) rats.

Conclusions: We found that Zincoderm G cream with zinc exhibited distinct killing profiles against P. aeruginosa.


Keywords


Zincoderm G cream, Pseudomonas aeruginosa, Infection, Burn-wound

Full Text:

PDF

References


Ninneman JL. Immunological defenses against infection: alterations following thermal injuries. J Burn Care Rehabil. 1987;3:355-66.

Winkelstein A. What are the immunological alterations induced by burn injury? J Trauma. 1984;24 9 Suppl: S72-83.

Pruitt BA Jr, McManus AT. The changing epidemiology of infection in burn patients. World J Surg. 1992;16(1):57-67.

Tredget EE, Shankowsky HA, Joffe AM, Inkson TI, Volpel K, Paranchych W, et al. Epidemiology of infections with Pseudomonas aeruginosa in burn patients: the role of hydrotherapy. Clin Infect Dis. 1992;15(6):941-9.

McManus AT, Mason AD Jr, McManus WF, Pruitt BA Jr. Twenty-five year review of Pseudomonas aeruginosa bacteremia in a burn center. Eur J Clin Microbiol. 1985;4(2):219-23.

Jacobsen F, Fisahn C, Sorkin M, Thiele I, Hirsch T, Stricker I, et al. Efficacy of topically delivered moxifloxacin against wound infection by Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2011;55(5):2325-34.

Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl. 1990;74:63-70.

Craig WA, Redington J, Ebert SC. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother. 1991;27 Suppl C:29-40.

Lacy MK, Nicolau DP, Nightingale CH, Quintiliani R. The pharmacodynamics of aminoglycosides. Clin Infect Dis. 1998;27(1):23-7.

Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin North Am. 2003;17(3):503-28, v.

Bryan LE, Kwan S. Roles of ribosomal binding, membrane potential, and electron transport in bacterial uptake of streptomycin and gentamicin. Antimicrob Agents Chemother. 1983;23(6):835-45.

Davis BD. Mechanism of bactericidal action of aminoglycosides. Microbiol Rev. 1987;51(3):341-350.

Taber HW, Mueller JP, Miller PF, Arrow AS. Bacterial uptake of aminoglycoside antibiotics. Microbiol Rev. 1987;51(4):439-57.

Cooper GL, Louie A, Baltch AL, Chu RC, Smith RP, Ritz WJ, et al. Influence of zinc on Pseudomonas aeruginosa susceptibilities to imipenem. J Clin Microbiol. 1993;31(9):2366-70.